Processa Pharmaceuticals Inc (NASDAQ: PCSA) is -70.51% lower on its value in year-to-date trading and has touched a low of $0.15 and a high of $3.10 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PCSA stock was last observed hovering at around $0.25 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $0.26, the stock is 6.75% and -27.61% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.97 million and changing 5.85% at the moment leaves the stock -72.89% off its SMA200. PCSA registered -88.47% loss for a year compared to 6-month loss of -77.44%.
The stock witnessed a -23.35% gain in the last 1 month and extending the period to 3 months gives it a -58.77%, and is 13.60% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 17.64% over the week and 25.44% over the month.
Processa Pharmaceuticals Inc (PCSA) has around 10 employees, a market worth around $1.38M and $0.00M in sales. Distance from 52-week low is 73.73% and -91.59% from its 52-week high. The company has generated returns on investments over the last 12 months (-698.44%).
The EPS is expected to grow by 75.19% this year.
Processa Pharmaceuticals Inc (PCSA) Top Institutional Holders
The shares outstanding are 5.27M, and float is at 4.63M with Short Float at 43.51%.
Processa Pharmaceuticals Inc (PCSA) Insider Activity
The most recent transaction is an insider purchase by Yorke Justin W, the company’s Director. SEC filings show that Yorke Justin W bought 12,400 shares of the company’s common stock on Jan 27 ’25 at a price of $0.80 per share for a total of $9889.0. Following the purchase, the insider now owns 12400.0 shares.
Processa Pharmaceuticals Inc disclosed in a document filed with the SEC on Jan 27 ’25 that Ng George K (Chief Executive Officer) bought a total of 87,200 shares of the company’s common stock. The trade occurred on Jan 27 ’25 and was made at $0.80 per share for $69542.0. Following the transaction, the insider now directly holds 87200.0 shares of the PCSA stock.
Still, SEC filings show that on Jan 27 ’25, Young David (Pres. Research & Development) acquired 124,500 shares at an average price of $0.80 for $99289.0. The insider now directly holds 205,405 shares of Processa Pharmaceuticals Inc (PCSA).
